Biotechnology 2019 & Enzymology 2019: A multiparametric analysis of the synergistic impact of anti-Parkinson's drugs on the fibrillation of human serum albumin

Tajalli Ilm Chandel, Nida Zaidi, Masihuz Zaman, Ishrat Jahan, Aiman Masroor, Ibrar Ahmad Siddique, Shahid M Nayeem, Maroof Ali, Vladimir N Uversky, Rizwan Hasan Khan

Interdisciplinary Biotechnology Unit-Aligarh Muslim University, IndiaNational Institute of Immunology, IndiaAligarh Muslim University, IndiaMoradabad Institutes of Technology, IndiaInstitute for Biological Instrumentation-RAS, RussiaKing Abdulaziz University, Saudi ArabiaUSF Health Byrd Alzheimer's Research Institute-University of South Florida, USA

E-mail: tajalli_chandel@yahoo.co.in

Abstract

Protein aggregation has been associated with several human neurodegenerative diseases, such as Parkinson's and Alzheimer's diseases. There are several small molecules that can reduce aggregation of proteins. The present study aimed to test the hypothesis that the application of more than one inhibitor either simultaneously or consecutively may result in more efficient inhibition of protein aggregation. To this end, the anti-amyloidogenic behaviour of benserazide hydrochloride (BH) and levodopa (LD) individually and in combination (BH + LD) was investigated using various biophysical, microscopic and computational techniques. BH, LD, and BH+LD treatments showed inhibitory effects on protein aggregation and had the ability to minimize the amyloid-induced cytotoxicity in human neuroblastoma cell line (SH-SY5Y). The two drugs in combination showed synergism (combination index, CI < 1) between them. These drugs also destabilized the preformed fibrils of human serum albumin (HSA). Our studies consistently showed that the BH+LD treatment showed highest efficacy towards inhibition and disaggregation of amyloid fibrils in comparison to treatment with BH and LD individually. Therefore, application of drugs in combination against fibrillogenesis may represent a new route for the development of means for prevention or delaying of the aggregation-related diseases.

This work is partly presented at Joint Event on 22nd Global Congress on Biotechnology & 5th International Conference on Enzymology and Protein Chemistry on February 28-March 02, 2019 held in Berlin, Germany

Joint Event on 22nd Global Congress on Biotechnology & 5th International Conference *Feb 28-March 02, 2019 | Berlin, Germany*

Volume 5, Issue 2